ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSR01

RTSS-Voice: Towards a unified system to classify treatments for muscle tension dysphonia

Active
Institution
Massachusetts General Hospital, MA
Principal investigator
Jarrad Van Stan
Funding
$583K
Duration
2022–2027
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary Systematically improving upon current voice therapy outcomes is problematic as the specific clinician actions (i.e., ingredients) responsible for improved patient functioning (i.e., targets) are unknown. For example, Comparative Effectiveness Research (CER) can show that therapy A works better than therapy B on global outcome X. But why did therapy A provide better outcomes? Why did some patients in therapy B significantly improve with the “worse” program; and some patients in therapy A remain unchanged with the “better” program? A theory-based system is needed to scientifically identify a program’s ingredients associated with improved outcomes across patients. And standard labels are needed to make the identified active ingredients generalizable across therapy programs. Therefore, this project will use a theory-driven framework for describing the ingredients/targets of rehabilitation treatments—called the Rehabilitation Treatment Specification System (RTSS)—and standard voice-specific terminology/definitions—called the RTSS-Voice— to standardly describe (Aim 1) and compare (Aim 2) variations in treatment across 9 well-known and diverse voice therapies. Also, we will create/test an implementation toolkit to facilitate RTSS-Voice adoption in clinical care across 5 Voice Centers (Aim 3). It is hypothesized that the RTSS and RTSS-Voice will characterize all therapies without needing revisions (Aim 1) and identify ingredients/targets that are unique to one therapy and/or common across multiple therapies (Aim2). And since the RTSS-Voice will help clinicians think about their treatment more specifically and in relation to 9 evidence-based therapies, we hypothesize adoption will be associated with improved outcomes at all 5 Voice Centers. The resulting list of mutually exclusive ingredient/targets across therapy programs will obviously improve the state of CER by enabling the identification/comparison of active ingredients across therapy programs; instead of the current practice of studying/comparing entire programs. Clinical adoption will result in large datasets with standard ingredients linked to outcomes, which will facilitate innovative hypotheses and interpretable datamining/machine learning to realistically improve voice therapy effectiveness. This work is likely to generalize to other Centers due to the involvement of >20 influential clinicians and the implementation toolkit.

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSMotor Function, Speech and Rehabilitation Study Section[MFSR]toolkittherapyvoiceassociated improvedimproved outcomesingredientsdidcer

Questions for Massachusetts General Hospital

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.